Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

at the European Association for the Study of Diabetes meeting in Madrid. Novo Nordisk’s oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection for chronic ...

Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an ...

At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S (NYSE:NVO) shared an abstract with data from the company’s next-generation weight loss candidate ...

Novo Nordisk's experimental weight-loss pill, amycretin, demonstrated safety and tolerability in early-stage trials. The pill showed significant weight reduction, with patients losing up to 13.1% of ...

Novo Nordisk's Saxenda, a weight-loss drug, significantly reduced BMI in children aged 6 to under 12 in a 56-week trial. The study, presented at a medical meeting, showed improvements in blood ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the ...

COPENHAGEN, Sept 11 (Reuters) - Novo Nordisk's highly anticipated experimental ... at the European Association for the Study of Diabetes meeting in Madrid later on Wednesday.